FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
ours per respons	se 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response			1										
Name and Address of Reporting Person * Ciechanover Isaac E.			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900			3. Date of Earliest Transaction (Month/Day/Year) 08/22/2017					X Officer (give title below) Other (specify below) Chief Executive Officer						
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				cable Line)		
(City		(State)	ZA 94080 (Zip)			_								
		(5)									osed of, or I			la 37 .
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			-	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Beneficially Owned Following Reported Transaction(s)			Ownership Form:	Beneficial		
			(Month/Day/Year)	Code	V	Amoun	(A) or t (D)	Price	(Instr. 3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common	Stock		08/22/2017		S(1)		2,200	D	\$ 13.56 (2)	443,978		I	See footnote (3)	
Common	Stock		08/23/2017		S(1)		2,200	D	\$ 13.51 (4)	441,778		I	See footnote (3)	
Common	Stock									737,767	7		D	
Reminder: indirectly.	Report on a	separate line	for each class of sec	urities beneficially	owned dir	ectly (or							
						con the	tained i form di	n this i	form ar a curre	e not req	ection of in uired to re d OMB cor	spond un	less	EEC 1474 (9- 02)
				Derivative Securiti [e.g., puts, calls, wa							i			
Security	Conversion	3. Transaction Date (Month/Day	Execution D (Year) any	4. ate, if Transaction Code (Instr. 8)	5. Number 6. Date Exercication of and Expiration Derivative (Month/Day/Y		on Date	Am Und Sec	Title and ount of derlying urities ttr. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form o Derivat Securit Direct (or Indii	Ownershi y: (Instr. 4) (D)	
				Code V	(A) (D		te ercisable	Expirat Date	tion Title	Amount or e Number of Shares				

Reporting Owners

Ī	D 41 0 N (A11	Relationships					
Reporting Owner Name / Address		Director 10% Owner		Officer	Other		
	Ciechanover Isaac E. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		Chief Executive Officer			

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Isaac E. Ciechanover	08/24/2017
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$13.40 to \$13.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$13.40 to \$13.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.